Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net Injectafer Coverage & Prior Auth Update…
    Ask Trek AI about this page
    ModifiedHealth NetPolicy CA.CP PHAR.234

    Ferric Carboxymaltose (Injectafer) coverage

    Customize your policy alerts

    Sign up for Health Net Policy CA.CP PHAR.234 alerts

    Get alerted when Policy CA.CP PHAR.234 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity criteria, prior authorization and continuation rules for ferric carboxymaltose (Injectafer) for commercial, HIM and Medicaid lines of business in Health Net of California.

    Policy Summary
    PayerHealth Net
    PolicyFerric Carboxymaltose (Injectafer) coverage
    Policy CodePolicy CA.CP PHAR.234
    Change TypeStep therapy update & redirection to preferred agents
    Effective DateMay 1, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation demonstrating failure or intolerance to specified preferred IV iron agents and relevant labs.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    New California policy with redirection to two preferred IV iron products, one of which must be Feraheme (generic when available).

    Updated initial criteria to require failure of specified preferred injectable agents (Ferrlecit and Venofer for IDA with CKD; for IDA without CKD require failure of two of Ferrlecit, Infed, or Venofer) and added redirection to Feraheme if intolerance/contraindication to preferred agents.

    FDA-approved indication for iron deficiency with heart failure was added to the indications section.

    3 monthstypical approval duration
    <=1000 mgmax elemental iron per infusion
    Commercial,HIM,Medicaidlines of business covered
    >=1 yrage range
    J1439HCPCS code referenced

    Coverage and Medical Necessity Criteria

    Initial — IDA with CKD

    Initial Approval — Iron Deficiency Anemia with Chronic Kidney Disease (must meet ALL):

    CKD IDA initial: 1) Diagnosis of iron deficiency anemia (IDA) with chronic kidney disease (CKD). 2) IDA confirmed by either serum ferritin < 500 ng/mL OR transferrin saturation (TSAT) < 30%. 3) If member with CKD is not on hemodialysis/peritoneal dialysis, oral iron is not optimal due to one or more of: hemoglobin < 7 g/dL; severe or ongoing blood loss; symptomatic anemia; oral iron intolerance; inability to achieve therapeutic targets with oral iron; co‑existing condition refractory to oral iron. 4) Failure of at least one alternative IV iron product (example: Ferrlecit or Venofer) unless clinically significant adverse effects or contraindications to those agents are documented. 5) Dose does not exceed two 750 mg elemental iron infusions/injections (total 1,500 mg per course) or a single 1,000 mg elemental iron infusion/injection.see node text

    Approval duration: 3 months

    Initial — IDA without CKD

    Initial Approval — Iron Deficiency Anemia without Chronic Kidney Disease (must meet ALL):

    Non‑CKD IDA initial: 1) Diagnosis of iron deficiency anemia (IDA) without CKD. 2) IDA confirmed by laboratory criteria such as serum ferritin < 15 ng/mL (or < 30 ng/mL if pregnant), or serum ferritin < 41 ng/mL with low hemoglobin, TSAT <= 20%, absence of stainable iron in bone marrow, increased soluble transferrin receptor (sTfR) or sTfR‑ferritin index, or increased erythrocyte protoporphyrin. 3) Oral iron therapy is not optimal due to one or more of: TSAT < 12%; hemoglobin < 7 g/dL; symptomatic anemia; oral iron intolerance; severe or ongoing blood loss; inability to achieve therapeutic targets with oral iron; co‑existing condition refractory to oral iron. 4) Member does not have CKD at time of request. 5) Failure of at least one alternative IV iron (example: Ferrlecit, Infed, or Venofer) unless clinically significant adverse effects or contraindications documented; if those are failed, failure of generic Feraheme is required unless contraindicated. 6) Dose does not exceed two 750 mg elemental iron infusions/injections (total 1,500 mg per course) or a single 1,000 mg elemental iron infusion/injection.see node text

    Approval duration: 3 months

    Initial — Iron deficiency with heart failure

    Initial Approval — Iron Deficiency in Heart Failure (must meet ALL):

    Heart failure iron deficiency: 1) Diagnosis of iron deficiency confirmed by either ferritin < 100 ng/mL OR ferritin 100–300 ng/mL with TSAT < 20%. 2) Member meets all of: left ventricular ejection fraction (LVEF) < 45%; NYHA class II or III; age > 18 years. 3) Dose does not exceed 1,000 mg elemental iron per infusion/injection.see node text

    Approval duration: 3 months

    Initial — Cancer/chemotherapy‑induced anemia (off‑label)

    Initial Approval — Management of Cancer‑ and Chemotherapy‑Induced Anemia (off‑label) (must meet ALL):

    Cancer/chemo induced anemia: 1) Absolute or functional iron deficiency documented by laboratory criteria (examples include: absolute iron deficiency such as serum ferritin < 30 ng/mL; functional iron deficiency such as serum ferritin 30–500 ng/mL with TSAT < 50%, or serum ferritin 500–800 ng/mL with TSAT < 20% depending on classification). 2) Member is prescribed chemotherapy and therapy is prescribed by or in consultation with an oncologist. 3) Failure of one of the alternative IV iron products (Ferrlecit, Infed, or Venofer) unless clinically significant adverse effects or contraindications are documented. 4) If criteria 3 are met, failure of generic Feraheme is required unless contraindicated. 5) Dose must be within FDA maximum for any approved indication or be supported by practice guidelines or peer‑reviewed literature for the off‑label use (prescriber must submit supporting evidence).see node text

    Prescribed regimen must be FDA‑approved or NCCN recommended. Approval duration: 3 months

    Continuation Therapy

    Continued Therapy (must meet criteria):

    Continuation criteria general: 1) Member is currently receiving medication via the Centene benefit or previously met initial approval criteria (or continuity of care applies). 2) Documentation of laboratory results since the last IV iron administration consistent with the applicable indication (examples: serum ferritin < 500 ng/mL or TSAT < 30% for CKD; ferritin and TSAT thresholds per indication). 3) If request is for a dose increase, new dose must not exceed two 750 mg elemental iron infusions/injections (total 1,500 mg per course) or a single 1,000 mg elemental iron infusion/injection. 4) Documentation of prior failure/intolerance or contraindication to alternative IV iron products must be provided when applicable.see node text

    Approval duration: 3 months

    Initial Therapy and Indication-specific Requirements

    Covered when criteria in the policy are met, including documented indication and prior agent failures where required.

    Initial approval - IDA and CKD: Requires documented iron deficiency anemia indication; prior failure of Ferrlecit and Venofer for IDA with CKD per updated initial criteria.

    Redirection to preferred agents required per policy; see step therapy

    Initial approval - IDA without CKD: Requires documented iron deficiency anemia; failure of two of Ferrlecit, Infed, or Venofer prior to approval of ferric carboxymaltose per updated criteria.

    If member has intolerance or contraindication to all preferred injectable agents, redirection to Feraheme (generic when available) is required per policy

    Indication - Iron deficiency with heart failure: Coverage aligns with the FDA‑approved indication for iron deficiency in heart failure (NYHA class II or III); dosing depends on hemoglobin and NYHA class with specified dosing schedules.

    See dosing nodes for Hb‑based dosing

    Step Therapy / Redirection

    Stepwise redirection and continued therapy

    Redirection to preferred products: Policy redirects to two preferred IV iron products; at least one preferred product must be Feraheme (generic when available). Providers must document failure, intolerance, or contraindication to preferred agents as specified in the initial criteria prior to approval or request redirection per policy.

    Continued therapy redirection language applies to IDA with and without CKD

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized for coverage unless the provider submits adequate documentation of efficacy and safety in accordance with the applicable off‑label use policies (see CP.CPA.09 for commercial and HIM.PA.154 for health insurance marketplace, as applicable).

    Hypersensitivity to Injectafer (ferric carboxymaltose) or to any of its inactive components is a contraindication to use and precludes coverage.

    Requests for treatment of non‑FDA approved indications that are not addressed in this policy will not be authorized unless sufficient supporting evidence is provided per the applicable off‑label use policy for the member’s line of business (for example, CP.CPA.09 for commercial or HIM.PA.154 for health insurance marketplace).

    Coding references included in this policy are provided for informational purposes only; inclusion or omission of a code does not guarantee coverage. Coverage decisions are determined by whether the member meets the medical necessity criteria in this policy, and providers should follow current professional coding guidance when submitting claims.

    Initial Therapy: Indication-Specific Rules

    Initial therapy

    Initial therapy criteria by indication

    Initial overall: See indication‑specific initial criteria for CKD, non‑CKD IDA, heart failure, and cancer/chemotherapy‑induced anemia. All require diagnostic laboratory thresholds and documentation that oral iron is not optimal; many require failure of other IV iron products unless contraindicated.

    Dosing and Initial agent-failure requirements

    Initial dosing options and agent failure requirements

    Dosing option A: Two 750 mg IV infusions separated by at least 7 days for a cumulative dose of 1,500 mg per course. Treatment may be repeated as clinically indicated.
    Dosing option B: Single‑dose treatment course: 15 mg/kg up to a maximum of 1,000 mg (alternative single‑dose regimen).

    Continuation and Ongoing Therapy

    Continuation therapy

    Continuation therapy

    Continuation: Member currently receiving medication via Centene benefit or previously met initial approval criteria; required laboratory documentation since last IV iron (serum ferritin, TSAT as applicable to the indication). If request is for dose increase, new dose must not exceed two 750 mg infusions/injections (total 1,500 mg per course) or a single 1,000 mg infusion/injection. Failure of alternative IV iron agents must be documented when applicable.

    Continued therapy redirection

    Continued therapy and redirection language applied to IDA with and without CKD.

    Continued therapy redirection: Per health plan request, initial approval criteria redirect to continued therapy criteria for IDA with and without CKD. Redirection requires documentation of prior failures/intolerances to preferred agents; if member is intolerant or contraindicated to all preferred agents, redirection to generic Feraheme is required per policy.

    Policy simplified redirection language and removed age‑based redirection

    Step Therapy and Agent-Failure Requirements

    StepRequirementProvider documentation
    1Document prior failure, intolerance, or contraindication to specified alternative IV iron products before approving Injectafer. Examples of alternatives include Ferrlecit (sodium ferric gluconate), Venofer (iron sucrose), Infed (iron dextran), or Feraheme (ferumoxytol). For IDA with CKD the policy requires failure of Ferrlecit and Venofer; for IDA without CKD failure of two of Ferrlecit, Infed, or Venofer is required.Submit clinical records demonstrating prior therapy attempts, adverse reactions, or contraindications (e.g., chart notes, lab results, medication history) showing failure or intolerance to the listed alternative IV iron agents.
    2If prior failure of the listed alternatives has occurred, provider may proceed with approval of Injectafer within dosing limits (no more than two 750 mg infusions for a cumulative 1,500 mg course, or a single 1,000 mg infusion per policy dosing rules).Provide documentation of prior failed dosing regimens and the proposed Injectafer dosing; include serum ferritin, TSAT, and hemoglobin values supporting medical necessity.
    StepRedirection conditionRequired redirection and rationale
    1If the member has documented intolerance or contraindication to all preferred injectable agents specified by the policy (e.g., Ferrlecit and Venofer for IDA with CKD; two of Ferrlecit, Infed, or Venofer for IDA without CKD).Policy redirects to Feraheme (generic ferumoxytol) when the member cannot tolerate or has contraindications to all preferred agents; provider must document the intolerance/contraindication to support redirection.
    2When redirection to Feraheme is required, ensure prior failure or intolerance to other alternatives per indication-specific requirements before approval of Injectafer or alternative authorization pathways are considered.Include clinical evidence of adverse effects or contraindications to each preferred agent, and documentation of any trial of generic Feraheme if required by the indication (e.g., cancer/chemotherapy‑induced anemia sequence).

    Prior Authorization, Documentation, and Submission Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Providers must demonstrate that the member meets the applicable initial or continuation criteria and submit supporting clinical documentation. Requests will be reviewed for prior failure or intolerance of preferred IV iron agents and may be redirected to preferred products (including generic Feraheme when available) per step-therapy requirements.

    • Prior authorization required for Injectafer (ferric carboxymaltose) prior to administration.
    • Step therapy: initial and continued use requires documented failure or intolerance of specified preferred IV iron products; if member is intolerant or has contraindications to all preferred agents, redirection to generic Feraheme may be required.
    • Approval duration: typically 3 months for initial and continued therapy (per policy-specific criteria).
    Documentation Required

    Required Documentation

    Providers must submit clinical documentation supporting that the member meets all approval criteria. Acceptable documentation includes but is not limited to office chart notes, relevant laboratory results (e.g., hemoglobin, serum ferritin, TSAT), prior treatment history showing use and response to oral and/or alternative IV iron products, and documentation of contraindications or adverse reactions to preferred agents.

    Coding, Clinical Thresholds, and Dosing Reference

    HCPCS Codes referencedHCPCS
    J1439Injection, ferric carboxymaltose, 1 mg
    Serum ferritin
    CKD thresholdSerum ferritin < 500 ng/mL for IDA with chronic kidney disease (CKD).
    Pregnancy and non-CKDSerum ferritin < 15 ng/mL (or < 30 ng/mL if pregnant) as an example threshold for IDA without CKD.
    Heart failure rangeFerritin 100–300 ng/mL used in heart failure assessment (with TSAT criteria).
    Continuation monitoringSerum ferritin < 500 ng/mL can be used as a documented laboratory result since last IV iron for continued therapy in CKD indications.
    Transferrin saturation (TSAT)
    CKD thresholdTransferrin saturation (TSAT) < 30% for IDA with chronic kidney disease (CKD).

    Dose and Quantity Limits

    Injectafer (ferric carboxymaltose) — quantity limits
    Maximum per infusion (common)No more than two 750 mg elemental iron infusions/injections or a single 1,000 mg elemental iron infusion/injection (dose limits vary by indication).
    Two-dose course totalUp to 1,500 mg elemental iron per two-dose course (two 750 mg doses).
    Single-infusion maximumA single ferric carboxymaltose infusion/injection may deliver up to 1,000 mg elemental iron, per indication-specific limits.
    Ferric carboxymaltose (Injectafer) — dosing summary
    Two-dose course allowanceFerric carboxymaltose (Injectafer): up to 1,500 mg per two-dose course (two 750 mg doses).
    Single-dose allowanceAlternatively, a single-dose treatment course may be 15 mg/kg to a maximum of 1,000 mg.

    Site of Care and Administration

    Note

    Infusion center not specified

    Site of care for IV infusion administration is not specified in this portion of the policy.

    Note

    Infusion administration setting

    IV infusion preparation and administration typically occur in an appropriate infusion setting consistent with standard practice; ensure infusions are performed in an appropriate setting per usual clinical standards.

    Background and Product Information

    Injectafer (ferric carboxymaltose) is an intravenous iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients 1 year of age and older who are intolerant of or have an unsatisfactory response to oral iron; FDA‑approved indications include IDA in adults with non‑dialysis dependent chronic kidney disease and iron deficiency in adult patients with heart failure (NYHA class II/III) to improve exercise capacity.

    Definitions and Abbreviations

    Transferrin saturation (TSAT) — definition
    DefinitionTSAT: transferrin saturation, a laboratory measure used to assess iron availability and guide IDA diagnosis and therapy decisions.
    Use in criteriaTSAT thresholds (e.g., <30%, ≤20%, or <12% depending on indication) are used in policy diagnostic and treatment decisions.
    Appendix referenceTSAT is listed in Appendix B: Therapeutic Alternatives as an abbreviation used throughout the policy.
    Erythropoiesis stimulating agent (ESA)
    DefinitionESA: erythropoiesis stimulating agent (abbreviation defined in Appendix A).
    Contextual useESA is referenced in the policy appendices as part of anemia management terminology.

    Policy Revision History

    2024-07-24added

    Added criteria for NCCN‑supported indication of cancer- and chemotherapy‑induced anemia with redirection to preferred IV iron products.

    2024-04-24added

    Published new California policy operationalizing redirection to two preferred IV iron products (one must be generic Feraheme when available).

    2024-03-07revised

    Corrected NYHA class for the heart failure FDA‑approved indication in the policy.

    Policy Summary
    PayerHealth Net
    PolicyFerric Carboxymaltose (Injectafer) coverage
    Policy CodePolicy CA.CP PHAR.234
    Change TypeStep therapy update & redirection to preferred agents
    Effective DateMay 1, 2024
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation demonstrating failure or intolerance to specified preferred IV iron agents and relevant labs.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaInitial Therapy: Indication-Specific RulesContinuation and Ongoing TherapyStep Therapy and Agent-Failure RequirementsPrior Authorization, Documentation, and Submission RequirementsCoding, Clinical Thresholds, and Dosing ReferenceDose and Quantity LimitsSite of Care and AdministrationBackground and Product InformationDefinitions and AbbreviationsPolicy Revision History
    Agent failure requirements: Documented failure of specified alternative IV iron products is required before approval (examples include Ferrlecit, Venofer, Infed); for IDA with CKD require failure of Ferrlecit and Venofer; for IDA without CKD require failure of two of Ferrlecit, Infed, or Venofer. If those are intolerant/contraindicated, policy redirects to generic Feraheme per step therapy language.
    • Include recent laboratory values since the last IV iron administration (e.g., serum ferritin, TSAT, hemoglobin).
    • Provide documentation of prior therapies tried (oral iron, Ferrlecit, Venofer, Infed, etc.), dates of therapy, doses, and reasons for discontinuation (e.g., intolerance, adverse effects, lack of efficacy).
    • If requesting an off‑label indication, include supporting evidence per the off‑label use policy (CP.CPA.09 or applicable plan-specific off‑label policy).
    Step Therapy

    Step Therapy Requirement and Redirection to Preferred IV Iron

    Step therapy is required before approval. For IDA with CKD and IDA without CKD the policy requires documented failure of or intolerance to specified alternative IV iron products prior to approval of ferric carboxymaltose. If the member has failed or cannot tolerate all preferred injectable agents, the request may be redirected to generic Feraheme (when available) per the policy's step-wise redirection rules.

    • IDA with CKD: failure of Ferrlecit and Venofer is required before approval of ferric carboxymaltose unless both are contraindicated or cause clinically significant adverse effects.
    • IDA without CKD: failure of two of Ferrlecit, Infed, or Venofer is required before approval unless contraindicated or cause clinically significant adverse effects.
    • If the member has met failure/intolerance to the preferred agents, documentation must show dates and reasons for failure/intolerance; only then can continuation or redirection to Feraheme be considered.
    Non-CKD examplesTSAT ≤ 20% (examples used to confirm IDA without CKD) or TSAT < 12% indicating oral iron not optimal in some non-CKD scenarios.
    Heart failure criteriaTSAT < 20% used with ferritin 100–300 ng/mL to define iron deficiency in heart failure patients.
    Hemoglobin (Hgb/Hb)
    Severe anemia thresholdHemoglobin (Hgb/Hb) < 7 g/dL is listed as a condition where oral iron is not optimal and supports IV iron use.
    Heart failure dosing relationHemoglobin ranges (e.g., Hb < 10 g/dL; Hb 10–14 g/dL; Hb 14 to <15 g/dL) are used to determine specific heart failure dosing schedules for ferric carboxymaltose.
    Gender-specific referencePolicy references Hb thresholds in diagnostic context (e.g., serum ferritin < 41 ng/mL and Hb < 12 g/dL in women or < 13 g/dL in men as part of IDA criteria).
    Single-dose and course dosing
    Two-dose courseTwo 750 mg IV infusions separated by at least 7 days for a cumulative dose of 1,500 mg per course.
    Alternative single-dose regimenSingle-dose option of 15 mg/kg up to a maximum of 1,000 mg for a treatment course.
    Heart failure-specific dosingHeart failure regimens vary by Hb and body weight (examples include 1,000 mg on day 1 then 500–1,000 mg at week 6 depending on Hb); maximum single-infusion doses described per indication.
    Treatment repetitionTreatment may be repeated as clinically indicated within the dose limits noted for the indication.
    Chronic kidney disease (CKD)
    DefinitionCKD: chronic kidney disease (abbreviation defined in Appendix A).
    Clinical relevanceCKD is a specific indication context for IDA where different ferritin/TSAT thresholds and step therapy rules apply.
    Erythropoiesis stimulating agent (ESA)
    DefinitionESA: erythropoiesis stimulating agent (duplicate appendix definition).
    NoteTerm appears in Appendix A as part of standard abbreviation list for the policy.
    Hemoglobin (Hb)
    DefinitionHb: hemoglobin (abbreviation defined in Appendix A).
    Clinical roleHemoglobin thresholds are used in several indication-specific dosing and 'oral iron not optimal' criteria.
    Iron deficiency anemia (IDA)
    DefinitionIDA: iron deficiency anemia (abbreviation defined in Appendix A).
    Policy scopeIDA is the primary diagnosis addressed by the policy across indications (CKD, non-CKD, heart failure, cancer/chemo-induced anemia).
    Transferrin saturation (TSAT) — duplicate
    DefinitionTSAT: transferrin saturation (appendix definition; used interchangeably as TSAT in diagnostic thresholds).
    Diagnostic useTSAT values such as <30%, ≤20%, or <12% are applied in the policy to confirm iron deficiency depending on indication.
    2023-11-09revised

    Per health plan request, revised redirection language to require generic Feraheme and simplified template redirection language for preferred agents.

    2023-08-15revised

    Added redirections from initial approval criteria to continued therapy for IDA with and without CKD per health plan request.

    2023-06-19added

    Updated FDA‑approved indications to include iron deficiency with heart failure per updated prescribing information.

    2023-05-23revisedLatest

    Updated initial criteria to require failure of specified preferred injectable agents for IDA (Ferrlecit and Venofer for IDA with CKD; two of Ferrlecit, Infed, or Venofer for IDA without CKD) and added redirection to Feraheme if intolerance/contraindication to preferred agents.